Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average rating of “Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $46.43.

Several research analysts have weighed in on the stock. Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $26,000. KBC Group NV purchased a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $35,000. SG Americas Securities LLC boosted its holdings in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares during the period. Barclays PLC grew its position in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $556,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $21.21 on Tuesday. Dianthus Therapeutics has a one year low of $16.72 and a one year high of $33.77. The business’s 50 day moving average price is $23.16 and its 200 day moving average price is $26.21. The company has a market cap of $627.75 million, a price-to-earnings ratio of -8.48 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.